Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium pyruvate inhalation in stable COPD (phase II)
CTR20220404Phase 2Completed
- Sponsor
- Jiangsu Changtai Pharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Pyruvic acid in chronic obstructive pulmonary disease (COPD), sponsored by Jiangsu Changtai Pharmaceutical. Started Mar 2022; status: completed.
02
Drugs
Pyruvic acid
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20220404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220404.